David Weitz, Sebastian Meier-Ewert, Muz Mansuri, Thomas McKearn, Edward McNiff, Michael Petrone, John Slayback, Bruce MacMillan, William Kruka, Michael Knapp | GenomeWeb

Syrrx said last week that it had appointed David Weitz as general counsel and vice president of intellectual property. Weitz will develop, maintain, and defend the company’s IP as it moves toward preclinical drug development, the company said. Weitz was previously partner at the Palo Alto, Calif., law firm Wilson Sonsini Goodrich and Rosati, where he co-led patent prosecution.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.